arrow
A

Arielle J. Medford

mass general brig ham cancer institute
H指数:13
被引数:837

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability

转移性化生性三阴性乳腺癌对沙库巴曲珠单抗的应答及生物标志物靶向性

2026-09-300
PRE
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis

HR+/HER2−转移性乳腺癌中细胞周期蛋白依赖性激酶4/6抑制剂暴露后的循环基因组景观:一项回顾性多机构联盟分析

2025-08-160
OAAI
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

NF1基因改变与CDK4/6抑制剂耐药在激素受体阳性转移性乳腺癌中的从临床到基础研究的转化分析

2025-06-270
PRE
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis

循环肿瘤DNA在早期三阴性乳腺癌中的作用:一项系统评价和Meta分析

2025-03-120
OA
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer

转移性乳腺癌中种族差异、ctDNA谱、靶向治疗使用及结局

2025-02-261
OA
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)
2025-01-070
OA
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling

在转移性乳腺癌中整合机器学习预测的循环肿瘤细胞 (ctc) 和循环肿瘤DNA (ctDNA): 内分泌耐药分析的原理研究证明

2025-01-010
PRE
A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
2024-05-020
PRE
Differential genomic profiling of progesterone receptor (PR) negative, estrogen receptor (ER) positive HER2-negative metastatic breast cancer (MBC) through circulating tumor DNA
2024-05-020
PRE
Differences in ctDNA genomic profiles and outcomes of Black and White patients with metastatic breast cancer: results from a large multicenter consortium
2024-05-020
PRE
Integration of synonymous mutations and variants of unknown significance for basal and longitudinal characterization of metastatic breast cancer by circulating tumor DNA
2024-05-020
PRE